Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kamillin Konzentrat Robugen is a traditional herbal medicinal product containing a highly concentrated extract of chamomile flowers (Matricaria recutita). Developed and marketed by Robugen GmbH, it is produced from specially bred chamomile varieties and contains 95.8 g of extract per 100 ml of solution. The extract is rich in bioactive constituents such as levomenol ((-)-α-bisabolol), apigenin, apigenin-glucoside, and matricin, which contribute to its anti-inflammatory, antispasmodic, and antimicrobial properties. It is indicated for the relief of mild gastrointestinal cramps (oral use), cold symptoms (steam inhalation), and inflammatory or irritated skin and mucous membrane conditions, including the oral cavity, gums, and genital areas (topical use).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kamillin Konzentrat Robugen.